
When It Hits the Fan Is the Worm Turning on 'Fat Jabs'?
11 snips
Jan 14, 2026 Weight-loss injections are currently sparking heated debates, especially with recent research suggesting significant weight regain after discontinuation. The conversation shifts as the pharmaceutical industry faces potential PR dilemmas. Meanwhile, Trump's claims regarding oil firms' foreknowledge about Venezuela add complexity to public perception. The dynamics of communication strategies in both pharma and oil are explored. Lastly, insights from The Traitors showcase how PR skills can influence game tactics, raising questions about strategy and manipulation.
AI Snips
Chapters
Transcript
Episode notes
Media Anger Begets Political Risk
- Public anger and media coverage can trigger political backlash and poor regulation.
- That cycle can punish manufacturers even if they only supply the product, David Yelland observed.
Prepare PR Within Regulatory Limits
- Pharma must prepare robust PR despite regulatory limits on claims.
- Anticipate restrictions and plan controlled, compliant communications now, David Yelland recommended.
Private Access Creates Continuity Risk
- Most UK users access GLP-1 drugs privately, creating equity and continuity problems.
- Job loss or cost barriers could force stopping treatment and trigger rapid weight regain, David Yelland noted.
